

*A! cont.*

53. The method according to claim 43, wherein the two recombinant DNAs each include an identical transcriptional promoter.

54. The method according to claim 53, wherein the two recombinant DNAs are inserted in the same orientation.

55. The method according to claim 43, wherein the immuno-suppressive agent is injected both before and after injection of the adenovirus.

56. The method according to claim 43, wherein the immuno-suppressive agent and the recombinant adenovirus are injected simultaneously. --


#### REMARKS

Claims 1-25 have been cancelled and rewritten as new claims 26-56 in order to conform with US patent practice. In addition, new method claims 43-56 are supported at page 1, lines 3-9, page 5, lines 7-11, and page 8, lines 1-2. No new matter has been added.

Rhône-Poulenc Rorer Inc.  
Legal-Patents #3C43  
P.O. Box 5093  
Collegeville, PA 19426-0997  
Telephone: (610) 454-3839  
Facsimile: (610) 454-3808

Dated: 8/14/97

Respectfully submitted,



Paul F. Fehlner, Ph.D.  
Attorney for Applicants  
Registration No. 35,135